A Phase 3 interventional study of Dapagliflozin and Placebo in Chronic Kidney Disease, sponsored by AstraZeneca. Completed at 392 sites in 21 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-07-07.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing dapagliflozin in Renal Insufficiency, Chronic — 15 open to participants now, 21 under way, 7 of them phase 3. dapagliflozin · Renal Insufficiency, Chronic.
Among the 40 studies testing dapagliflozin in Renal Insufficiency, Chronic, this one is the 3rd largest by enrollment, is one of 2 that started in 2017, is one of 10 in phase 3, and was the 2nd registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →15 of the 40 studies testing dapagliflozin in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 24 more countries
Ages 18–99
Centenario Hospital Miguel Hidalgo · Sites in Mexico
Ages 14–18
Oman Ministry of Health · Sites in Oman
Ages 13+
Peter Rossing · Sites in Denmark, Germany, Spain and 1 more country
Ages 18–75
Ain Shams University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 11 · Phase 4 11
First in 2015; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,304 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 100 across the 40 interventional studies. Of the 18 that completed or were terminated, 3 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 40 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
54 studies in Renal Insufficiency, Chronic by AstraZeneca: 6 open now, 11 under way, 5 of them phase 3. Of 43 finished, 18 (42%) have results posted.
Among the 54 studies in Renal Insufficiency, Chronic by AstraZeneca, this one is the 3rd largest by enrollment of the 38 interventional ones that give a count, is the only one that started in 2017, is one of 10 in phase 3, and was the 3rd registered.
AstraZeneca’s Renal Insufficiency, Chronic studies by the year they started, since 2003.
6 of the studies testing dapagliflozin in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
| NCT06155604The University of Hong KongSGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease | 2026-12-31 |
| NCT07678203Hospital Civil Juan I. MenchacaDapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis | 2027-01-28 |
| NCT07405216Centenario Hospital Miguel HidalgoEfficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease | 2027-05-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 40 studies testing dapagliflozin in Renal Insufficiency, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 54 in Renal Insufficiency, Chronic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease.
This is an international, multicentre, event-driven, randomized, double-blind, parallel group, placebo-controlled study, evaluating the effect of dapagliflozin versus placebo, given once daily in addition to standard of care, to prevent the progression of chronic kidney disease (CKD) or cardiovascular (CV)/renal death.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be randomized 1:1 to either dapagliflozin or placebo.
Drug: Dapagliflozin
Placebo matching dapagliflozin.
Drug: Placebo
10 mg or 5 mg tablets given once daily, per oral use.
Also known as: Forxiga TM, Farxiga TM
Placebo matching dapagliflozin 10 mg or 5 mg
Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death.
End Stage Renal Disease (ESRD) is defined as: * Sustained eGFR \<15 mL/min/1.73m2 or, * Chronic dialysis treatment or, * Receiving a renal transplant The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.
Time frame: Up to 38.2 months
Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or Renal Death.
End Stage Renal Disease (ESRD) is defined as: * Sustained eGFR \<15 mL/min/1.73m2 or, * Chronic dialysis treatment or, * Receiving a renal transplant The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.
Time frame: Up to 38.2 months
Time to the First Occurrence of Either of the Components of the Composite: CV Death or Hospitalization for Heart Failure.
The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.
Time frame: Up to 38.2 months
Time to Death From Any Cause.
The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.
Time frame: Up to 38.2 months
| Milestone | Dapagliflozin | Placebo |
|---|---|---|
| Started | 2152 | 2152 |
| Completed | 2142 | 2147 |
| Not completed | 10 | 5 |
| Withdrew: Withdrawal by subject | 8 | 3 |
| Withdrew: Lost to follow-up | 2 | 2 |
End Stage Renal Disease (ESRD) is defined as: * Sustained eGFR \<15 mL/min/1.73m2 or, * Chronic dialysis treatment or, * Receiving a renal transplant The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.
| Participants | Dapagliflozin | Placebo |
|---|---|---|
| Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death. | 197 | 312 |
End Stage Renal Disease (ESRD) is defined as: * Sustained eGFR \<15 mL/min/1.73m2 or, * Chronic dialysis treatment or, * Receiving a renal transplant The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.
| Participants | Dapagliflozin | Placebo |
|---|---|---|
| Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or Renal Death. | 142 | 243 |
The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.
| Participants | Dapagliflozin | Placebo |
|---|---|---|
| Time to the First Occurrence of Either of the Components of the Composite: CV Death or Hospitalization for Heart Failure. | 100 | 138 |
The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.
| Participants | Dapagliflozin | Placebo |
|---|---|---|
| Time to Death From Any Cause. | 101 | 146 |
Collected over Up to 39.2 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dapa 10 mg | 107/2,152 (5%) | 633/2,149 (29.5%) | 479/2,149 (22.3%) |
| Placebo | 159/2,152 (7.4%) | 729/2,149 (33.9%) | 500/2,149 (23.3%) |
| Event | Dapa 10 mg | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 44/2149 | 70/2149 |
| Cardiac failureCardiac disorders | 39/2149 | 59/2149 |
| Acute kidney injuryRenal and urinary disorders | 39/2149 | 52/2149 |
| Acute myocardial infarctionCardiac disorders | 32/2149 | 46/2149 |
| End stage renal diseaseRenal and urinary disorders | 26/2149 | 36/2149 |
| Chronic kidney diseaseRenal and urinary disorders | 20/2149 | 31/2149 |
| Ischaemic strokeNervous system disorders | 22/2149 | 28/2149 |
| DeathGeneral disorders | 15/2149 | 27/2149 |
| Angina unstableCardiac disorders | 14/2149 | 22/2149 |
| Cardiac failure congestiveCardiac disorders | 13/2149 | 22/2149 |
| Event | Dapa 10 mg | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 92/2149 | 81/2149 |
| Urinary tract infectionInfections and infestations | 78/2149 | 79/2149 |
| HypoglycaemiaMetabolism and nutrition disorders | 74/2149 | 70/2149 |
| Renal impairmentRenal and urinary disorders | 51/2149 | 64/2149 |
| Oedema peripheralGeneral disorders | 54/2149 | 63/2149 |
| HypertensionVascular disorders | 62/2149 | 60/2149 |
| Glomerular filtration rate decreasedInvestigations | 39/2149 | 61/2149 |
| HyperkalaemiaMetabolism and nutrition disorders | 53/2149 | 49/2149 |
| Back painMusculoskeletal and connective tissue disorders | 44/2149 | 50/2149 |
| Acute kidney injuryRenal and urinary disorders | 49/2149 | 44/2149 |
| Age, Continuous(Years) | Dapagliflozin | Placebo | Total |
|---|---|---|---|
| Mean | 61.8 ± 12.1 | 61.9 ± 12.1 | 61.8 ± 12.1 |
| Age, Customized(Participants) | Dapagliflozin | Placebo | Total |
|---|---|---|---|
| <= 50 years | 362 | 370 | 732 |
| > 50 years | 1790 | 1782 | 3572 |
| Age, Customized(Participants) | Dapagliflozin | Placebo | Total |
|---|---|---|---|
| <= 65 years | 1247 | 1239 | 2486 |
| > 65 years | 905 | 913 | 1818 |
| Age, Customized(Participants) | Dapagliflozin | Placebo | Total |
|---|---|---|---|
| <=65 years | 1247 | 1239 | 2486 |
| 66-75 years | 663 | 667 | 1330 |
| > 75 years | 242 | 246 | 488 |
| Sex: Female, Male(Participants) | Dapagliflozin | Placebo | Total |
|---|---|---|---|
| Female | 709 | 716 | 1425 |
| Male | 1443 | 1436 | 2879 |
| Ethnicity (NIH/OMB)(Participants) | Dapagliflozin | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 522 | 550 | 1072 |
| Not Hispanic or Latino | 1630 | 1602 | 3232 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Dapagliflozin | Placebo | Total |
|---|---|---|---|
| White | 1124 | 1166 | 2290 |
| Black or African American | 104 | 87 | 191 |
| Asian | 749 | 718 | 1467 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| American Indian or Alaska Native | 62 | 74 | 136 |
| Other | 112 | 106 | 218 |
| Most likely etiology of CKD(Participants) | Dapagliflozin | Placebo | Total |
|---|---|---|---|
| Diabetic Nephropathy | 1271 | 1239 | 2510 |
| Ischaemic/Hypertensive Nephropathy | 324 | 363 | 687 |
| Chronic Glomerulonephritis | 343 | 352 | 695 |
| Other or unknown cause of CKD | 214 | 198 | 412 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 392 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2017 to primary completion in Jun 2020, 40 months.
Results were first posted in Jul 2021, 1 year after primary completion.
Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 40 months is above that.
Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin
Renal Insufficiency, Chronic →